Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av C-KIT-specifika antikropps-läkemedelskonjugat NN3201 för avancerade och/eller metastatiska fasta tumörer som är kända för att uttrycka C-KIT

9 november 2026 uppdaterad av: Novelty Nobility, Inc.

En fas 1-dosupptrappning och expansionsstudie av C-KIT-specifika antikropp-läkemedelskonjugat NN3201 hos personer med avancerade och/eller metastatiska fasta tumörer som är kända för att uttrycka C-KIT

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

Studieöversikt

Detaljerad beskrivning

The drug being tested in this study is called NN3201, a c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE, administered by IV. The study will be conducted in two parts, a dose escalation phase (Part A) followed by an expansion phase (Part B).

The patient population for the dose escalation phase (Part A) of the study will include patients with advanced and/or metastatic c-Kit-associated solid tumors including gastrointestinal stromal tumor (GIST), adenoid cystic carcinoma (ACC), uveal melanoma, neuroendocrine tumors (NET), and chromophobe and clear cell renal cell carcinomas (ChRCC and ccRCC). For Part A patients must have received treatment with imatinimb for GIST or be progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for cKit-associated solid tumors (ACC, uveal melanoma, NET, ChRCC, or ccRCC). The primary objective of the dose escalation phase (Part A) is to determine the safety profile of NN3201 administered by IV, including the incidence and severity of adverse events (AEs), serious adverse events (SAEs), and dose-limited toxicities (DLTs) as well as the incidence of abnormal laboratory findings and abnormal vital signs. Part A will help determine the maximum tolerated dose (MTD) and/or the recommended dose(s) (RDEs) for the expansion phase (Part B).

Once a recommended dose has been determined in the escalation phase (Part A), the expansion phase (Part B) will assess the safety and efficacy of NN3201 when administered at 2 RDE dose levels to subjects in two indication-specific (GIST and SCLC) expansion cohorts and one basket cohort for c-Kit positive solid tumors (excluding GIST and SCLC). All cohorts in Part B will utilize the same eligibility criteria as in Part A.

Cohort B1 - GIST: up to 10 subjects with GIST will be enrolled at the MTD level (RDE1) and efficacy and safety as well as any available PK and PD data will be evaluated.

Cohort B2 - SCLC: up to 10 SCLC will be enrolled at 1 dose level below MTD (MTD-1/RDE2) and efficacy and safety as well as any available PK and PD data will be evaluated. The Scientific Review Committee (SRC) may decide to enroll and additional 10 subjects in SCLC subjects.

Cohort B3 - c-Kit-associated solid tumors: in this basket cohort, up to 10 subjects with any c-Kit-associated solid tumor (including ACC, uveal melanoma, NET, ChRCC, and ccRCC and excluding GIST and SCLC) will be enrolled.

The safety and tolerability of NN3201 administered intravenously (IV) at up to two RDEs in subjects with advanced and/or metastatic solid tumors is the primary objective for Part B.

Studietyp

Interventionell

Inskrivning (Beräknad)

67

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109-9001
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • Rekrytering
        • Case Comprehensive Cancer Center
        • Kontakt:
          • Ankit Mangla, MD
        • Kontakt:
    • Oregon
      • Portland, Oregon, Förenta staterna, 97239
        • Rekrytering
        • Oregon Health & Science University
        • Kontakt:
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • The University of Texas MD Anderson Cancer Center
        • Kontakt:
        • Kontakt:
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • Aktiv, inte rekryterande
        • NEXT Virginia

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

Subjects must meet the following criteria to be eligible for enrollment into the study:

  1. Histologically or cytologically confirmed locally advanced, metastatic, and/or unresectable GIST, SCLC, ACC, uveal melanoma, NET ChRCC or ccRCC.

  2. Subjects must have received the following treatment:

    Part A (Dose Escalation):

    i. Treatment with imatinib for GIST (at least one line of therapy with imatinib)

    or

    ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET ChRCC or ccRCC)

    Part B (Dose Expansion):

    i. Treatment with imatinib for GIST (at least one line of therapy with imatinib) or

    ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for Extensive stage SCLC or

    iii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET or ChRCC or ccRCC).

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  4. Life expectancy ≥ 3 months before starting NN3201 in the opinion of the Investigator.

  5. Age ≥ 18 years.

  6. Laboratory values demonstrating adequately functioning kidney, liver and bone marrow (hematology).

  7. Adequate heart function as measured by ECHO/MUGA scan.

  8. Time between prior anticancer therapy including investigational agents and first dose of NN3201 as below:

    1. Cytotoxic chemotherapy - At least 21 days
    2. Non-cytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days
    3. Nitrosoureas - At least 6 weeks
    4. Monoclonal antibody(ies) - At least 28 days
    5. Radiotherapy - At least 14 days from local site radiation therapy
  9. Negative Serum/urine pregnancy test (for subjects of childbearing potential)

  10. All subjects of childbearing potential must agree to use contraception throughout the study and for additional 120 days after the last dose of assigned treatment. Subjects must refrain from donating sperm during the same period or Subjects who do not have childbearing potential are confirmed post-menopausal or sterile.

  11. Voluntary agreement to provide written informed consent and have willingness and ability to comply with all aspects of the protocol.

Key Exclusion Criteria:

  1. Has received prior therapy with a c-Kit agent (except GIST subjects).
  2. Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms.
  3. A condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to administration of study drugs (inhaled corticosteroids are allowed).
  4. Any prior treatment-related (i.e., chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at Study Entry, Day -2 to Cycle 1 Day 1.
  5. Major surgery within 30 days before the first dose of study drug treatment in Cycle 1 on Day 1 (port placement for venous access is not considered major surgery).
  6. Significant cardiovascular impairment.
  7. Significant screening electrocardiogram (ECG) abnormalities.
  8. Known active and clinically significant bacterial, fungal, or viral infection.
  9. Uncontrolled hypertension defined as systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg, despite optimal medical management.
  10. Venous thrombosis or pulmonary embolism within the last 3 months prior to the screening.
  11. Ongoing or active infection requiring intravenous treatment with anti-infective therapy or systemic therapy and/or any identified active COVID-19 infection.
  12. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.
  13. People who are pregnant or breastfeeding.

Other inclusion and exclusion criteria must also be met to be eligible to participate in this study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part A

NN3201 administered intravenously every three weeks, the dosage to be determined by ascending dose cohort assignment. Part A will enroll patients that have GIST or Other c-Kit tumor disease types. This is an open-label multiple ascending dose study.

A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Experimentell: Part B, Cohort 1 (GIST)

NN3201 administered intravenously every three weeks, expanding one or two doses in GIST disease type. This is an open-label multiple dose expansion study.

A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Experimentell: Part B, Cohort 2 (SCLC)

NN3201 administered intravenously every three weeks, expanding one or two doses in SCLC disease type. This is an open-label multiple dose expansion study.

A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Experimentell: Part B, Cohort 3 (other c-Kit tumors)

NN3201 administered intravenously every three weeks, expanding one or two doses in Other c-Kit tumor disease type. This is an open-label multiple dose expansion study.

A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of subjects with Dose-limiting Toxicities:
Tidsram: 3 weeks

A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 21 days after the first dose of study treatment.

3 weeks
Incidence of Adverse Events:
Tidsram: 1 year

Number of subjects with adverse events (AEs) according to severity, seriousness, and relationship to study drug

1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Choose which dose(s) will be used in the expansion cohorts
Tidsram: 1 year

Assessing which dose(s) have anti-tumor benefit and an acceptable incidence of adverse events that allow for continued enrollment

1 year
Pharmacokinetics (PK) of NN3201
Tidsram: 3 years

Pharmacokinetics (PK) of NGM120 by measuring serum concentration of NGM120 at specified timepoints

3 years
Assessment of anti-tumor activity
Tidsram: 3 years

Assessment of anti-tumor activity by RECIST 1.1

3 years
Choose which dose(s) may be used in a future study
Tidsram: 3 years

Assessing which dose(s) have anti-tumor benefit and an acceptable incidence of adverse events that may be used in a future study.

3 years

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Immunogenicity against NN3201
Tidsram: 3 years

Immunogenicity against NN3201 by measuring percentage of subjects to develop antidrug antibodies and neutralizing antibodies

3 years
Correlation Between Pharmacokinetic (PK) and Pharmacodynamic (PD) Variables, Safety, and Efficacy
Tidsram: 3 yeas

Evaluation of the correlation between PK parameters (e.g., Cmax, AUC) and PD effects (e.g., changes in target biomarkers), and their relationship to safety outcomes (e.g., incidence of adverse events) and efficacy outcomes (e.g., objective response rate and progression-free survival).

3 yeas
Changes in Biomarker Levels in Response to Treatment
Tidsram: At baseline and specified intervals over 3 years.

Investigation of changes in specific biomarkers (e.g., soluble c-Kit) during treatment to assess their relationship to treatment response.

At baseline and specified intervals over 3 years.
Correlation Between Baseline Biomarker Levels and Clinical Response/Toxicity
Tidsram: 3 years

Assessment of the relationship between baseline levels of specific biomarkers (e.g., soluble c-Kit, tumor c-Kit expression) and clinical outcomes, including response to treatment and incidence of toxicity.

3 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Sunil Sharma, MD, Novelty Nobility

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 februari 2025

Primärt slutförande (Beräknad)

30 augusti 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

8 januari 2025

Först inskickad som uppfyllde QC-kriterierna

28 januari 2025

Första postat (Faktisk)

3 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NN3201-ST100

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera